[go: up one dir, main page]

WO2009006473A3 - Pro-soft polypeptide proteasome inhibitors, and methods of use thereof - Google Patents

Pro-soft polypeptide proteasome inhibitors, and methods of use thereof Download PDF

Info

Publication number
WO2009006473A3
WO2009006473A3 PCT/US2008/068910 US2008068910W WO2009006473A3 WO 2009006473 A3 WO2009006473 A3 WO 2009006473A3 US 2008068910 W US2008068910 W US 2008068910W WO 2009006473 A3 WO2009006473 A3 WO 2009006473A3
Authority
WO
WIPO (PCT)
Prior art keywords
pro
polypeptide
soft
methods
proteasome inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/068910
Other languages
French (fr)
Other versions
WO2009006473A2 (en
Inventor
William W Bachovchin
Hung-Sen Lai
David George Sanford
Wengen Wu
Paul Everill
Sarah E Poplawski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of WO2009006473A2 publication Critical patent/WO2009006473A2/en
Publication of WO2009006473A3 publication Critical patent/WO2009006473A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Aspects of the present invention relate to pro-drug forms of chemotherapeutic compounds, which forms selectively target cancerous cells, thereby reducing the discomfort and deleterious side effects associated with systemic administration of the chemotherapeutic compounds. The present invention also relates to use of said pro-drug forms in the treatment of hyperproliferative diseases, cancers, and the like.
PCT/US2008/068910 2007-07-05 2008-07-01 Pro-soft polypeptide proteasome inhibitors, and methods of use thereof Ceased WO2009006473A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94803207P 2007-07-05 2007-07-05
US60/948,032 2007-07-05

Publications (2)

Publication Number Publication Date
WO2009006473A2 WO2009006473A2 (en) 2009-01-08
WO2009006473A3 true WO2009006473A3 (en) 2009-02-26

Family

ID=40226809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/068910 Ceased WO2009006473A2 (en) 2007-07-05 2008-07-01 Pro-soft polypeptide proteasome inhibitors, and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2009006473A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597410B2 (en) 2011-08-30 2017-03-21 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066386A (en) 2008-06-17 2011-05-18 米伦纽姆医药公司 Borate compound and its pharmaceutical composition
AR075090A1 (en) 2008-09-29 2011-03-09 Millennium Pharm Inc ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
BRPI1010147A2 (en) 2009-06-19 2019-09-24 Lek Pharmaceuticals process for preparing a compound, use of a process and use of an iridium catalyst
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
CN101928329B (en) 2009-06-19 2013-07-17 北京大学 Tripeptide boric acid (ester) compound and preparation method and application thereof
PH12012501943A1 (en) 2010-03-31 2017-08-23 Millennium Pharm Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid
CR20160577A (en) 2014-05-20 2017-01-06 Millennium Pharm Inc PROTEASOME INHIBITORS CONTAINING BORO TO BE USED AFTER A PRIMARY CANCER THERAPY
JP7164521B2 (en) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
CN109476637B (en) 2016-06-21 2022-02-01 奥瑞恩眼科有限责任公司 Heterocyclic prolinamide derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
WO2003105753A2 (en) * 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for grafting functional loops into a protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
WO2003105753A2 (en) * 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for grafting functional loops into a protein

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597410B2 (en) 2011-08-30 2017-03-21 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors
US9956297B2 (en) 2011-08-30 2018-05-01 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors
US10517955B2 (en) 2011-08-30 2019-12-31 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors

Also Published As

Publication number Publication date
WO2009006473A2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2009006473A3 (en) Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
WO2014031487A8 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
WO2009049184A9 (en) Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
NZ593641A (en) Extended soluble ph20 polypeptides and uses thereof
AU327035S (en) Shirt for sports
CA138374S (en) Boot
CA138376S (en) Boot
WO2013084000A3 (en) Exosomes for delivery of biotherapeutics
WO2008116053A3 (en) Fap-activated chemotherapeutic compounds, and methods of use thereof
CA138379S (en) Boot
WO2009099677A3 (en) Therapeutic peptidomimetic macrocycles
CA117735S (en) Shoe
WO2007118149A3 (en) Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
IL179738A0 (en) Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
AU2008339918A1 (en) Medicament for the treatment of cancer of the pancreas
WO2009155556A3 (en) Crkl targeting peptides
WO2010077589A3 (en) Stat3 inhibitors and therapeutic methods using the same
CA143665S (en) Boot
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
CA143664S (en) Boot
EP4065691A4 (en) Natural killer cell immunotherapy for the treatment of glioblastoma and other cancers
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
CA143666S (en) Boot

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08781230

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08781230

Country of ref document: EP

Kind code of ref document: A2